Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.
about
Three-drug versus two-drug induction therapy regimens for patients with transplant-eligible multiple myelomaNovel agents in the treatment of multiple myeloma: a review about the futureCancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and managementInternational Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationEvolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted TherapiesRecent advances in understanding multiple myelomaClinical use of proteasome inhibitors in the treatment of multiple myelomaThe choice of regimens based on bortezomib for patients with newly diagnosed multiple myelomaImpact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03.Bortezomib-induced thrombotic thrombocytopaenic purpuraOvercoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myelomaHematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma.Sustained remission and reversal of end-organ dysfunction in a patient with anaplastic myeloma.Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION studyProteasome inhibition and its therapeutic potential in multiple myelomaRemission of disseminated cancer after systemic oncolytic virotherapyOptimizing current and emerging therapies in multiple myeloma: a guide for the hematologist.Proteasome inhibitors in the treatment of multiple myelomaOverview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Multiple myeloma patients at various cytogenetic risks benefit differently from autologous stem cell transplantation as a consolidation therapyLenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trialInternational Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary reEfficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTDCarfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.Myeloma today: Disease definitions and treatment advances.Novel agent induction therapy alone or followed by autologous stem cell transplantation in younger patients with multiple myeloma: A single-center retrospective study of 114 cases.Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.Challenges in multiple myeloma diagnosis and treatment.Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in OncologyManagement of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelinesLenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.Current multiple myeloma treatment strategies with novel agents: a European perspectiveHow best to use new therapies in multiple myeloma.High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma.
P2860
Q24202358-E25D19A5-528E-4F51-9EC9-12FDC6963A0BQ26745924-778268B3-EF28-4F91-A00E-BDDAD3E4CF63Q26785497-054B0F28-406B-42F8-BBE3-50FDF5977E24Q26998884-6D4A44D8-FF00-4FAA-8EA6-2EB0A4C78AECQ27002668-7E78906A-3091-434C-9CFC-4CE132E4788FQ27026478-27B95FF5-4C6A-47DD-A52E-D8F8F5F60690Q28070331-88713317-4235-41A1-8A67-0CC4CF5CCB41Q28080999-21F936B7-52AE-48D7-8F23-6D98A00990C1Q28539605-BDF06F74-6BC5-4A13-903E-02DFF7669C4EQ30424188-91031D63-A9F3-4262-8C65-D352AB96B02DQ33402637-0FC0C1BA-3C93-4CDA-BE99-83C9341BE1C4Q33405532-8F054F1C-8580-4959-B542-AA7B28F98398Q33408056-E381C5B5-28AF-481E-8212-D6352A5C77C3Q33408698-1DECE4B3-F334-4EF2-B454-64114CE465A5Q33864685-496DA9CB-149B-4C74-BE56-A236D94DACBAQ34213649-9AC0DC18-40A2-49E4-8870-FA3A9EDEA671Q34343036-F3BEB971-4AB0-4D80-BAB8-F036125376EFQ34420326-8C87C1C3-BFBC-4632-8D6F-B35993E011EDQ34551324-3EE7085A-9AC7-44B9-BD5D-99F87FF683CCQ34611676-07AF28F7-C181-418E-BC6E-CDB22AF83EAFQ34788381-7D1E0AC6-AA42-4E7B-A7AE-CF865BA95557Q35061518-8869C5DF-6372-4D2F-861C-A724A9B97098Q35125893-8C116C88-9E09-4E65-BFDD-E2FC4217CCD4Q35802414-BD5A2D17-3828-46C2-998B-6C426759F16FQ35868171-C695CCB8-0947-4CB5-A511-5C7E2CADC11FQ36020680-782D3606-FE2D-4803-957D-55261079AA94Q36036322-84D71941-3F92-43B4-9228-DECA3186DF3FQ36162623-7A414091-C204-4AE9-947F-4164A8EC90C6Q36274834-7E7BCB15-E5DE-4DB1-B221-31D7EA9D8903Q36470699-35DB98D0-3840-4A9C-A494-832C833A8049Q36502820-FC6EAAF7-6900-4C64-A4A7-667D3DD76908Q36777233-AA0D430E-2A8C-444D-8E97-0324B6A8FBD6Q36852225-77E076D7-0EA2-46BE-A3B6-E5FE8F48EB66Q36963203-27C0949E-624D-41C6-8ACC-CFC00A2584ACQ37454445-E1702CC2-95D5-4DCF-99D1-6D7A88E98761Q37515416-BAED2197-7979-496C-92E6-144565FBC935Q37623809-C168E16B-392E-4A45-98F2-610F9A1D8494Q37677935-656C8DAE-519E-494A-82A4-B75247503764Q37723000-03ABA464-08F9-4579-99D2-62D2F82C7EFAQ37766453-D46AA746-459F-4A39-8122-F69E21DE5126
P2860
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Cyclophosphamide, bortezomib a ...... in a phase II clinical trial.
@ast
Cyclophosphamide, bortezomib a ...... in a phase II clinical trial.
@en
Cyclophosphamide, bortezomib a ...... in a phase II clinical trial.
@nl
type
label
Cyclophosphamide, bortezomib a ...... in a phase II clinical trial.
@ast
Cyclophosphamide, bortezomib a ...... in a phase II clinical trial.
@en
Cyclophosphamide, bortezomib a ...... in a phase II clinical trial.
@nl
prefLabel
Cyclophosphamide, bortezomib a ...... in a phase II clinical trial.
@ast
Cyclophosphamide, bortezomib a ...... in a phase II clinical trial.
@en
Cyclophosphamide, bortezomib a ...... in a phase II clinical trial.
@nl
P2093
P2860
P356
P1433
P1476
Cyclophosphamide, bortezomib a ...... s in a phase II clinical trial
@en
P2093
A K Stewart
C B Reeder
J R Mikhael
P2860
P2888
P304
P356
10.1038/LEU.2009.26
P577
2009-02-19T00:00:00Z
P5875
P6179
1040865864